Details for Patent: 11,510,878

Which drugs does patent 11,510,878 protect, and when does it expire?

Patent 11,510,878 protects ASPRUZYO SPRINKLE and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 11,510,878

Title:	Extended release multiparticulates of ranolazine
Abstract:	The present invention relates to an extended release multiparticulate composition comprising a plurality of discrete units, each discrete unit comprising ranolazine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The said multiparticulate composition is sprinkled onto soft foods or liquids for oral administration. Further, the multiparticulate composition is bioequivalent to the marketed extended release tablet. It further relates to a process of preparation of said multiparticulate composition and method of treatment of patients suffering from angina by administering said composition.
Inventor(s):	Harinder Singh, Shavej AHMAD, Romi B. Singh
Assignee:	Sun Pharmaceutical Industries Ltd
Application Number:	US17/129,167
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Device; Dosage form;

Drugs Protected by US Patent 11,510,878

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Spil	ASPRUZYO SPRINKLE	ranolazine	GRANULE, EXTENDED RELEASE;ORAL	216018-002	Feb 28, 2022		DISCN	Yes	No	11,510,878		Y
Spil	ASPRUZYO SPRINKLE	ranolazine	GRANULE, EXTENDED RELEASE;ORAL	216018-001	Feb 28, 2022		DISCN	Yes	No	11,510,878		Y

International Family Members for US Patent 11,510,878

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3409273